Mydecine Innovations Group Inc
Change company Symbol lookup
Select an option...
MYCOF Mydecine Innovations Group Inc
PPG PPG Industries Inc
VFFVX Vanguard Target Retirement 2055 Fund Investor Shares
LUB Luby's Inc
AZO Autozone Inc
RMAX Re/Max Holdings Inc
SWET Athlon Acquisition Corp
ETR Entergy Corp
KUBTY Kubota Corp
PTEN Patterson-UTI Energy Inc
Go

Consumer Staples : Tobacco | Small Cap Value
Based in Canada
Company profile

Mydecine Innovations Group Inc. is a Canada-based biopharma and life sciences company. The Company is focused on the research, development and acceptance of alternative nature-sourced medicine. Its portfolio of companies includes Mydecine Health Sciences (MHS), Mindleap Health Inc. (Mindleap) and NeuroPharm, Inc (NPI). MHS is focused on developing fungtional mushroom products and psychedelic medicines for the consumer and professional healthcare market. NPI is a veterans-focused healthcare company that is developing pharmaceutical and natural health products for mental wellness in vulnerable populations, including veterans, emergency medical services (EMS) personnel and other high-risk constituencies. NPI is developing psilocybin-assisted psychotherapy to treat chronic post-traumatic stress disorder (PTSD). Mindleap offers a digital health platform that enables people connect with mental health specialists, who can help them to develop habits for a healthy mind.

Closing Price
$0.2718
Day's Change
-0.0031 (-1.13%)
Bid
--
Ask
--
B/A Size
--
Day's High
0.28
Day's Low
0.25
Volume
(Light)
Volume:
398,195

10-day average volume:
678,724
398,195

Company Profile

Mydecine Innovations Group Inc. is a Canada-based biopharma and life sciences company. The Company is focused on the research, development and acceptance of alternative nature-sourced medicine. Its portfolio of companies includes Mydecine Health Sciences (MHS), Mindleap Health Inc. (Mindleap) and NeuroPharm, Inc (NPI). MHS is focused on developing fungtional mushroom products and psychedelic medicines for the consumer and professional healthcare market. NPI is a veterans-focused healthcare company that is developing pharmaceutical and natural health products for mental wellness in vulnerable populations, including veterans, emergency medical services (EMS) personnel and other high-risk constituencies. NPI is developing psilocybin-assisted psychotherapy to treat chronic post-traumatic stress disorder (PTSD). Mindleap offers a digital health platform that enables people connect with mental health specialists, who can help them to develop habits for a healthy mind.

Valuation Ratios

Price/Earnings (TTM)
--
Price/Sales (TTM)
305.31x
Price/Book (MRQ)
7.25x
Price/Cash Flow (TTM)
--
TTM = Trailing Twelve Months
MRQ = Most Recent Quarter

Price Performance

Historic Growth and Share Detail

Historic Growth

Annual growth, past 5 years
EPS
Revenue
Dividend No Regular Dividend is paid
 

Short Interest

No short interest available.

Share Information

MYCOF is in a share class of common stock
Float
131.3M
Shares Outstanding
235.4M
Institutions Holding Shares
3
1.77%

Financial Statements

Balance sheet

Values displayed are in thousands.

Income statement

Values displayed are in thousands.

Cash flow

Values displayed are in thousands.

Company Officers

No company officers listed.

Address

Insider Trading

No insider trading activity.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Insider trading information report provided by Copyright © 2021. All rights reserved.

Reuters content is the intellectual property of Reuters. Any copying, republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters is not liable for any errors or delays in content, or for any actions taken in reliance on any content. Reuters, Reuters Logo and the Sphere Logo are trademarks and registered trademarks of the Reuters Group of companies around the world.

Data is provided for information purposes only and is not intended for trading purposes. Reuters shall not be liable for any errors or delay in the content, or for any action taken in reliance on any content. The RIC or Reuters Instrument Code set has been developed and maintained by Reuters and is the intellectual property of Reuters.